DRR1 is expressed in the developing nervous system and downregulated during neuroblastoma carcinogenesis

Biochemical and Biophysical Research Communications

Volumn 394, Issue 3, 2010, Pages 829-835

  Asano, Yoshizumi ^a   Kishida, Satoshi ^a   Mu, Ping ^a   Sakamoto, Kazuma ^a   Murohara, Toyoaki ^a   Kadomatsu, Kenji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinogenesis; DRR1; Nervous system; Neuroblastoma; Tumor suppressor gene

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELIAC GANGLION; CELL SURVIVAL; CONTROLLED STUDY; DRR1 GENE; EMBRYO; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENE MAPPING; HUMAN; HUMAN CELL; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURITE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CENTRAL NERVOUS SYSTEM; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; NEUROGENESIS; NEURONS; NUCLEAR PROTEINS; PERIPHERAL NERVOUS SYSTEM; RATS; TUMOR SUPPRESSOR PROTEINS;

MUS; MUS MUSCULUS; RATTUS;

EID: 77950520601     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.085     Document Type: Article

References (18)

1. Yamato T., Orikasa K., Fukushige S., Orikasa S., and Horii A. Isolation and characterization of the novel gene, TU3A, in a commonly deleted region on 3p14.3→p14.2 in renal cell carcinoma. Cytogenet. Cell Genet. 87 (1999) 291-295
2. Wang L., Darling J., Zhang J.S., Liu W., Qian J., Bostwick D., Hartmann L., Jenkins R., Bardenhauer W., Schutte J., Opalka B., and Smith D.I. Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. Genes Chromosomes Cancer 27 (2000) 1-10
3. van den Boom J., Wolter M., Blaschke B., Knobbe C.B., and Reifenberger G. Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. Int. J. Cancer 119 (2006) 2330-2338
4. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., and Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (1984) 1121-1124
5. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., and Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16 (1997) 2985-2995
6. Hansford L.M., Thomas W.D., Keating J.M., Burkhart C.A., Peaston A.E., Norris M.D., Haber M., Armati P.J., Weiss W.A., and Marshall G.M. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc. Natl. Acad. Sci. USA 101 (2004) 12664-12669
7. Kadomatsu K., Hagihara M., Akhter S., Fan Q.W., Muramatsu H., and Muramatsu T. Midkine induces the transformation of NIH3T3 cells. Br. J. Cancer 75 (1997) 354-359
8. Krichevsky A.M., and Kosik K.S. RNAi functions in cultured mammalian neurons. Proc. Natl. Acad. Sci. USA 99 (2002) 11926-11929
9. Zabarovsky E.R., Lerman M.I., and Minna J.D. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21 (2002) 6915-6935
10. Wulfkuhle J.D., Donina I.E., Stark N.H., Pope R.K., Pestonjamasp K.N., Niswonger M.L., and Luna E.J. Domain analysis of supervillin, an F-actin bundling plasma membrane protein with functional nuclear localization signals. J. Cell Sci. 112 Pt 13 (1999) 2125-2136
11. Ting H.J., Yeh S., Nishimura K., and Chang C. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc. Natl. Acad. Sci. USA 99 (2002) 661-666
12. Crowley J.L., Smith T.C., Fang Z., Takizawa N., and Luna E.J. Supervillin reorganizes the actin cytoskeleton and increases invadopodial efficiency. Mol. Biol. Cell 20 (2009) 948-962
13. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr. 17 (2005) 7-13
14. Mosse Y.P., Diskin S.J., Wasserman N., Rinaldi K., Attiyeh E.F., Cole K., Jagannathan J., Bhambhani K., Winter C., and Maris J.M. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 46 (2007) 936-949
15. Hoebeeck J., Michels E., Menten B., Van Roy N., Eggert A., Schramm A., De Preter K., Yigit N., De Smet E., De Paepe A., Laureys G., Vandesompele J., and Speleman F. High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. Int. J. Cancer 120 (2007) 533-538
16. Vanaja D.K., Ballman K.V., Morlan B.W., Cheville J.C., Neumann R.M., Lieber M.M., Tindall D.J., and Young C.Y. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin. Cancer Res. 12 (2006) 1128-1136
17. Kholodnyuk I.D., Kozireva S., Kost-Alimova M., Kashuba V., Klein G., and Imreh S. Down regulation of 3p genes, LTF, SLC38A3 and DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int. J. Cancer 119 (2006) 99-107
18. Awakura Y., Nakamura E., Ito N., Kamoto T., and Ogawa O. Methylation-associated silencing of TU3A in human cancers. Int. J. Oncol. 33 (2008) 893-899